Report Categories
View AllRecent Articles
View All
Precision Aerospace Defense and FACT II Acquisition Corp File Amended S4 for Proposed Business Combination
JLong JL Climbs 124 Resistance at 681 in Focus 20260518
Milestones from Shors Algorithm to Googles Willow Chip How Quantum Computings Decade Away Timeline Is Evolving
Amplify AMPY Q1 2026 Results Miss Estimates EPS 093 vs 006
PowerFleet AIOT Slides 093 as Selling Pressure Mounts 20260521
SpaceX IPO Could Propel Elon Musk to Historic Trillionaire Status
Dreamland TDIC Q2 2025 Earnings No Surprises But Whats Next
Birla Capital Plans 4000 Crore Preferential Issue IFC Among Investors
Eicher Motors Reports Surge in Q4 Net Profit to 1520 Crore Plans 3400 Crore Investment
Pfizer Prevails in Singapore Trademark Dispute with Merck Over Vaccine Brand
Gold and Silver Settle Lower as Precious Metals Continue Recent Declines
Berkshire Hathaway Rebuilds Airline Exposure with 26 Billion Delta Stake
UK Intelligence Chief Warns West Faces Moment of Consequence from RussiaChina Threats
Bank of America Forecasts Fed Rate Cut Delay Until Second Half of 2027
LPA Q1 2026 Earnings Net Loss Reported Amid Quiet Market Response
BCAB Q4 2025 Earnings NarrowerThanExpected Loss Drives Positive Sentiment
PNBK Q1 2019 Earnings Significant EPS Miss Amid Challenging Banking Environment
ASMB Q1 2026 Earnings Narrowed Loss and Pipeline Progress Boost Investor Sentiment
GECC Q1 2026 Earnings EPS Beats Estimates by 126 Amid Stable Operations
Johnson Outdoors JOUT Stages a Modest Rebound Key Levels to Watch
Pineapple Financial Inc PAPL Drops 455 as Support Level at 10 Comes into Focus
Spruce Biosciences SPRB Edges Higher Testing Key Resistance Near 5440
Ingevity NGVT Edges Higher Amid Quiet Trading Holds Above Key Support
Drill Tools DTI Q1 2026 Earnings Miss EPS 003 vs 002 Expected
Standard Chartered CEO Moves to Calm Staff Concerns Over AIDriven Workforce Changes
EchoStar Corporation SATS Blows Past Q1 2026 Forecasts EPS Hits 028
Imax Corporation IMAX Climbs 426 Resistance at 3623 in Focus 20260520
Vera Therapeutics VERA Q1 2026 Earnings Miss Sparks Concern
Genesis GEL Reports Weak Q1 2026 Cost Pressures Weigh on Margins